AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19857702 — intervention group
Group type: EXPERIMENTAL
Intervention: HFSS
Number of subjects: 658
Study 19857702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of NTproBNP, hsCRP, and HFSS
Number of subjects: 658
Study 19857702 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint (death or urgent transplantation)
Number of subjects: 658
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD gene variant
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: UGT1A1 gene variant
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1 gene variant
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexpression of G6PD African A- mutation with UGT1A1 and/or SLCO1B1 variants
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors contributing to hyperbilirubinemia
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO blood group heterospecificity (mother had blood group O)
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive direct Coombs test results
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling treated with phototherapy
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal circulating blood group antibodies
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diabetes mellitus
Number of subjects: 452
Study 19858149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal East Asian ethnicity
Number of subjects: 452
Study 19858174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritious, culturally appropriate daily meal (weeks 1-8) and food package (weeks 9-32) (n=137)
Number of subjects: 270
Study 19858174 — intervention group
Group type: COMPARATOR
Intervention: Nutritional advice (n=133)
Number of subjects: 270
Study 19858174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive results on sputum smears receiving nutritious meal
Number of subjects: 270
Study 19858174 — intervention group
Group type: COMPARATOR
Intervention: Patients with positive results on sputum smears receiving nutritional advice
Number of subjects: 270
Study 19858707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided conservative procedure (mini-mesohepatectomy)
Number of subjects: 17
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham risk model
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE risk model
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP >or=2 mg/l in patients without prior CVD and LDL <3.4 mmol/l
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 539
Study 19858725 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 539
Study 19858759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 19863224 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell-based vaccination with allogeneic melanoma cell lysate
Number of subjects: 0
Study 19864401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of fish (1-2 servings, 25-50 g/week)
Number of subjects: 204
Study 19864401 — intervention group
Group type: COMPARATOR
Intervention: <101 g fish/week
Number of subjects: 204
Study 19864401 — intervention group
Group type: COMPARATOR
Intervention: >=101 g fish/week
Number of subjects: 204
Study 19875605 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood infusion
Number of subjects: 15
Study 19875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported TV-viewing time
Number of subjects: 40
Study 19875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective TV-viewing time measured by electronic monitors
Number of subjects: 40
Study 19875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported TV-viewing time vs. objective measure
Number of subjects: 40
Study 19875989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported viewing time accuracy
Number of subjects: 40
Study 19877976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439
Study 19877976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439
Study 19877976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and Cognitive-Behavioral Therapy (COMB)
Number of subjects: 439
Study 19877976 — intervention group
Group type: COMPARATOR
Intervention: Pill Placebo (PBO)
Number of subjects: 439
Study 19877976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) or Cognitive-Behavioral Therapy (CBT)
Number of subjects: 439
Study 19879222 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin (rHA)
Number of subjects: 869
Study 19879222 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 869
Study 19879222 — intervention group
Group type: COMPARATOR
Intervention: Both rHA and TIV
Number of subjects: 869
Study 19879566 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vacuum-assisted closure (E-VAC)
Number of subjects: 8
Study 19880144 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial left atrial appendage clip placement
Number of subjects: 34
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression classifier predictive of relapse-free survival (RFS)
Number of subjects: 207
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression classifier
Number of subjects: 207
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric measures of minimal residual disease (MRD)
Number of subjects: 207
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined gene expression classifier
Number of subjects: 207
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene expression classifier predictive of end-induction MRD
Number of subjects: 207
Study 19880498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression classifiers
Number of subjects: 207
Study 19880781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter flow cytometry
Number of subjects: 765
Study 19880781 — intervention group
Group type: COMPARATOR
Intervention: Conventional morphology
Number of subjects: 765
Study 19880906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT (HRCT) scanning
Number of subjects: 92
Study 19880906 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (TST) and QuantiFERON TB Gold In-Tube (QFT) test
Number of subjects: 92
Study 19880906 — intervention group
Group type: COMPARATOR
Intervention: CXR
Number of subjects: 92
Study 19880908 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained patients (n = 10)
Number of subjects: 17
Study 19880908 — intervention group
Group type: COMPARATOR
Intervention: Untrained patients (n = 7)
Number of subjects: 17
Study 19882494 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional hearing aids for 1 month
Number of subjects: 94
Study 19882494 — intervention group
Group type: COMPARATOR
Intervention: Omnidirectional hearing aids for 1 month
Number of subjects: 94
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior participation in pulmonary rehabilitation
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater exercise capacity
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception of being disabled
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid use
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime sleepiness
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-breath diffusing capacity of the lung for carbon monoxide percent predicted
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test distance
Number of subjects: 0
Study 19882497 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV(1)
Number of subjects: 0
Study 19886987 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly)
Number of subjects: 29
Study 19887595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 3 weeks
Number of subjects: 0
Study 19887595 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin treatment
Number of subjects: 0
Study 19887595 — intervention group
Group type: EXPERIMENTAL
Intervention: AICAR treatment
Number of subjects: 0
Study 19887595 — intervention group
Group type: COMPARATOR
Intervention: Control (Ionomycin treatment)
Number of subjects: 0
Study 19888782 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin embonate (pamoate) 22.5 mg, two consecutive intramuscular injections at an interval of 24 weeks
Number of subjects: 120
Study 19889129 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine-ER 8-24 mg/day for 4 months
Number of subjects: 19
Study 19889129 — intervention group
Group type: COMPARATOR
Intervention: Baseline (healthy volunteers)
Number of subjects: 19
Study 19889129 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine-ER treatment
Number of subjects: 19
Study 19889232 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human methionyl leptin (r-metHuLeptin)
Number of subjects: 4
Study 19889232 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of leptin during six weeks
Number of subjects: 4
Study 19889819 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg phytosterols/d
Number of subjects: 18
Study 19889819 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg phytosterols/d
Number of subjects: 18
Study 19889819 — intervention group
Group type: COMPARATOR
Intervention: 59 mg phytosterols/d (control)
Number of subjects: 18
Study 19889819 — intervention group
Group type: EXPERIMENTAL
Intervention: 459 mg phytosterols/d
Number of subjects: 18
Study 19890127 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptide-based erythropoietin-receptor agonist (Hematide); administered subcutaneously at an initial dose of 0.05 mg/kg every 4 weeks
Number of subjects: 14
Study 19890203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir 400 mg and Ritonavir 100 mg, given twice daily for 4 weeks
Number of subjects: 8
Study 19891771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index monitor (BIS) with electronic alerts if BIS value is >60
Number of subjects: 30000
Study 19891771 — intervention group
Group type: COMPARATOR
Intervention: Minimum alveolar concentration (MAC) with electronic alerts if age-adjusted MAC is <0.5
Number of subjects: 30000
Study 19892043 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination at Year 5
Number of subjects: 0
Study 19892043 — intervention group
Group type: COMPARATOR
Intervention: No booster vaccination at Year 5 (unboosted)
Number of subjects: 0
Study 19892043 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at Year 20 for both groups
Number of subjects: 0
Study 19892587 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene transfer using aquaporin-1 cDNA via a recombinant adenoviral vector
Number of subjects: 0
Study 19897179 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-dose intravenous ketamine (six infusions over 12 days)
Number of subjects: 10
Study 19897553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 137
Study 19897553 — intervention group
Group type: COMPARATOR
Intervention: Flexible bronchoscopy
Number of subjects: 137
Study 19897553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound following negative flexible bronchoscopy
Number of subjects: 137
Study 19898830 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (commuting and leisure-time)
Number of subjects: 4031
Study 19898830 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 4031
Study 19898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp test
Number of subjects: 38
Study 19898832 — intervention group
Group type: COMPARATOR
Intervention: OGTT
Number of subjects: 38
Study 19898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp-derived functional variables
Number of subjects: 38
Study 19898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low first-phase C-peptide response
Number of subjects: 38
Study 19898832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low second-phase C-peptide response
Number of subjects: 38
Study 19901114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg on days 1-21 of a 28-day cycle) plus high-dose dexamethasone (40 mg on days 1-4, 9-12, and 17-20 for the first four cycles, then 40 mg on days 1-4 only thereafter)
Number of subjects: 353
Study 19901114 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation
Number of subjects: 353
Study 19901114 — intervention group
Group type: COMPARATOR
Intervention: Control group (dexamethasone plus placebo)
Number of subjects: 353
Study 19901191 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted high-density lipoprotein (rHDL) infusion (CSL-111; 20 mg . kg(-1) . h(-1)) for 4 hours
Number of subjects: 0
Study 19901191 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study 19902266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for patent ductus arteriosus (PDA)
Number of subjects: 148
Study 19902266 — intervention group
Group type: COMPARATOR
Intervention: No ibuprofen treatment
Number of subjects: 148
Study 19902266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for PDA
Number of subjects: 148
Study 19906082 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravitreal injection of triamcinolone combined with bevacizumab
Number of subjects: 0
Study 19906082 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19906624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir and emtricitabine once daily plus nevirapine twice daily
Number of subjects: 10
Study 19906626 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATV) and Lopinavir/Ritonavir (LPV/r)
Number of subjects: 10
Study 19906626 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 10
Study 19907027 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elevation of IOP to an average of 64 mm Hg for less than 30 seconds in one eye of all subjects.
Number of subjects: 100
Study 19909496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (high intensity levels > 3.9 g)
Number of subjects: 35
Study 19909496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (first three months of exercise exceeding 1.1 g)
Number of subjects: 35
Study 19909496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (first three months of activity)
Number of subjects: 35
Study 19909496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (0-6 months' impacts)
Number of subjects: 35
Study 19909496 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact training (6 months of training)
Number of subjects: 35
Study 19909747 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 75
Study 19909747 — intervention group
Group type: COMPARATOR
Intervention: Virtual chromoendoscopy
Number of subjects: 75
Study 19910250 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical diagnosis using high-definition white light, narrow-band imaging without magnification, and chromoendoscopy as required.
Number of subjects: 130
Study 19910250 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical diagnosis alone for determining surveillance intervals.
Number of subjects: 130
Study 19912627 — intervention group
Group type: EXPERIMENTAL
Intervention: TABADO program (smoking cessation program combining pharmacologic and cognitive-behavioral strategies)
Number of subjects: 2000
Study 19912627 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention (control group)
Number of subjects: 2000
Study 19914605 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the nucleus accumbens (NAcc)
Number of subjects: 10
Study 19915292 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of etidronate cyclically
Number of subjects: 44
Study 19915292 — intervention group
Group type: COMPARATOR
Intervention: High-dose glucocorticoids (GCs)
Number of subjects: 44
Study 19915602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter clinical trials in pediatric oncology
Number of subjects: 0
Study 19915602 — intervention group
Group type: COMPARATOR
Intervention: Neonatology intensive care units (NICUs)
Number of subjects: 0
Study 19915888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan patients undergoing CPET
Number of subjects: 38
Study 19915888 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 38
Study 19916704 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 171
Study 19916705 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 21729
Study 19916705 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 (treatment-naïve subgroup)
Number of subjects: 21729
Study 19916705 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 (OADs only subgroup)
Number of subjects: 21729
Study 19916705 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 (insulin +/- OADs subgroup)
Number of subjects: 21729
Study 19917888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 4000
Study 19917888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 19918104 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lopinavir/ritonavir 200/50 mg tablet formulation (400/100 mg twice daily)
Number of subjects: 37
Study 19918104 — intervention group
Group type: COMPARATOR
Intervention: Kaletra(R) soft-gel capsules
Number of subjects: 37
Study 19918104 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic ritonavir
Number of subjects: 37
Study 19918104 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lopinavir/ritonavir tablet
Number of subjects: 37
Study 19920002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2005
Study 19920002 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2005
Study 19920002 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2005
Study 19920002 — intervention group
Group type: COMPARATOR
Intervention: Insulin provision
Number of subjects: 2005
Study 19920002 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 2005
Study 19920114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg twice daily
Number of subjects: 47
Study 19920114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 47
Study 19920114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (both dosages)
Number of subjects: 47
Study 19920819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with metronomic etoposide (10 mg kg(-1) bevacizumab biweekly and 50 mg m(-2) etoposide daily for 21 consecutive days each month)
Number of subjects: 59
Study 19920819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with metronomic etoposide
Number of subjects: 59
Study 19922035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention 'Obeldicks'
Number of subjects: 248
Study 19922035 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leptin concentrations
Number of subjects: 248
Study 19922036 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment methods (pediatrician referral and targeted mailings)
Number of subjects: 164
Study 19922036 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment methods
Number of subjects: 164
Study 19922036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatrician referral
Number of subjects: 164
Study 19922036 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment costs
Number of subjects: 164
Study 19922631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 100
Study 19922631 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 100
Study 19922631 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 100
Study 19923206 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops to improve supervision frequency
Number of subjects: 0
Study 19923206 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision process
Number of subjects: 0